Like Pfizer's BNT162b2 and Moderna's mRNA-1273, it requires two doses. 2023 InvestorPlace Media, LLC. Copyright Learn More. Those lessons will vary between different investors, but I'll point out a major one to keep in mind. Realistically, Ocugen is probably looking at potential approval of Covaxin in mid-2023 at the earliest. 7 Penny Stocks Poised for Explosive Growth in 2023, Ocugen Stock Is Not for the Faint of Heart. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! All rights reserved. Lorem ipsum dolor sit amet, consectetur adipiscing elit. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. According to the prospectus, the combined company posted an operating loss of roughly $30 million in 2018. 1125 N. Charles St, Baltimore, MD 21201. The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. After all, one cannot expect Ocugen stock to cure its ills when the company itself has fallen into critical condition. CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants. Custom BMW. 7 Travel Stocks to Buy Banking On Pent-Up Demand. Still, this stock is cheap for reasons that my colleague Josh Enomoto spelled out well. Some were undoubtedly anticipating a relatively quick EUA win for Covaxin followed by strong U.S. sales for the COVID-19 vaccine. One thing seems certain, however:Ocugens fate as an investment is closely tied to the ultimate outcome of Covaxin. Keith Speights owns shares of Pfizer. Related Link: If You Invested $1,000 In Moderna Stock One Year Ago, Here's How Much You'd Have Now. CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. That's not going to happen now. Investors were hopeful that the small drugmaker would be able to win U.S. It has real products. How can we possibly evaluate a stock on a fundamental basis with that being reality? Buy These 2 Stocks in 2023 and Hold for the Next Decade, 2 Stocks That Are About to Make Their Shareholders Richer, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, the company's fourth-quarter conference call last month, Copyright, Trademark and Patent Information. However, due to the fact the details of the definitive agreement have yet to be finalized, in addition to the current lack of insight into the U.S. regulatory pathway or commercial strategy, Ramakanth stays on the sidelines for now. Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 4.75, with a high estimate of 8.00 and a low estimate of 3.00. However, I wont be around to find out. Copyright 2023 InvestorPlace Media, LLC. Not an offer or recommendation by Stocktwits. Please check your download folder. It brings in no revenue. With this, the newly formed Ocugen initiated a 60:1 reverse stock split. 1125 N. Charles St, Baltimore, MD 21201. Ocugens Big Run: One company that has been a home-run investment in the last year has been biotech stock Ocugen Inc (NASDAQ:OCGN). Its all about choice. The worst news was that another late-stage clinical study will likely be required to support the regulatory filing. It took Moderna roughly 10 months from the initiation of the late-stage study for its COVID-19 vaccine to the point where the company filed for full FDA approval. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. The biotech stock promptly crashed by more than 30%. In 2018, its NeoCart biologic failed to meet the primary endpoint of its own Phase III trial. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Do not expect a recovery in Ocugen stock. Pricing likely would be favorable, given the lack of alternative treatments. So far, that merger hasnt worked out for Histogenics former shareholders. These options will be cheaper than owning the stock itself. Names like Ocugen (NASDAQ:OCGN) arent trading for about 50 cents apiece by accident. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days. For most of its history, what we now know as Ocugen stock was Histogenics, a cell therapy company focused on orthopedics. The point is, the risk/reward of owning something like Ocugen is simply not worth it vs. having even basic equity exposure. (See OCGN stock analysis on TipRanks). Why Ocugen Stock Is Crashing Today By Keith Speights - Mar 4, 2022 at 11:42AM Key Points The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Making the world smarter, happier, and richer. Historical daily share price chart and data for Ocugen since 2023 adjusted for splits. Keith Speights for Investing is always a game of balancing risk and reward. Concerns about the delta variant, the potential need for annual booster shots and the possibility of expanding the vaccines to children have investors hopeful that Covaxin will still eventually be a huge payoff for Ocugen. This is most likely a result of the stocks meteoric rise and analysts inability to turnaround new price targets so quickly. The generic form of brimonidine, the active ingredient, is not approved for the condition, according to Ocugens most recent presentation. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. Conditions only seem to get worse for Ocugen (NASDAQ:OCGN). *ALL INFO ABOUT THE BIKE AND GEAR USED DOWN BELOW**If not listed it's left stock*BIKE: 2018, BMW R NINET SCRAMBLER.EXHAUST: Akrapovic Headers, Uni. Ocugen isnt a promotional, fly-by-night penny stock. Investors should worry about companies with no revenue even under the best of circumstances. In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. Ocugen In 2021, Beyond: Optimism about Covaxin coupled with massive short squeezes in a handful of popular social media stocks sent Ocugen shares skyrocketing up to as high as $18.77 in February 2021. The company does not earn revenue, relying on grants, a dwindling cash position, and stock dilution to keep its doors open. When the market crashed during the U.S. pandemic outbreak in March, shares of vaccine makers understandably soared as work began on developing vaccines to fight COVID-19. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Nasdaq The Ocugen 52-week high stock price is 4.03, which is 328.7% above the current share price. If OCU300 is approved, theres a reasonably large market. Type a symbol or company name. By the beginning of March, the stock was still trading at 45 cents as news of the coronavirus spreading in China prompted concerns about a U.S. pandemic. But realizing value in practice usually is a difficult endeavor. The Ocugen deal is a way to salvage some limited value. The steep decline came after the company announced that the U.S. Food and Drug Administration (FDA) won't grant Emergency Use Authorization (EUA) for COVID-19 vaccine Covaxin in children ages two to 18. Some investors had set their hopes on the FDA being more lenient with pediatric use of Covaxin. Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. To make the world smarter, happier, and richer. But the sale of NeoCart appears to not yet have closed after its deadline was extended to allow Medavate to secure financing. Another alternative is to sell some or all of your Ocugen stock and invest the money elsewhere. Even at around 40 cents per share, I would consider Ocugen stock overvalued. Matthew McCall left Wall Street toactually helpinvestors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. This decision isn't surprising, considering that Ocugen previously abandoned the pursuit of an EUA path for the vaccine in adults. The reverse merger with Histogenics was a disappointment, but the purchase price for the NeoCart intellectual property suggests that company had little chance of survival on its own. The reverse merger that brought Ocugen to the public markets led to huge losses but some investors are buying the dip. Theres an opportunity here. In November, Bharat Biotech began Phase 3 testing of Covaxin in India. And its at least possible that OCGN could wind up being a winner. But it does mean something. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. Theres even room for more lines. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. While anything is possible, I would not anticipate a miracle here. As with many biotech stocks, the most likely outcome is for the company to fail, and for shareholders to wind up with zero. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. There's no way, however, to know what the COVID-19 vaccine market dynamics will be two years from now. All rights reserved. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. For priority reviews, the timeline for an approval decision is reduced to six months. As of this writing, Matt did not hold a position in any of theaforementioned securities. The Motley Fool has a disclosure policy. But any success they find will be without me as a shareholder. It announced on Dec. 9 of last year 17 months later that it was 50% through enrollment. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. Ocugen Inc. stock rises Wednesday, outperforms market Feb. 22, 2023 at 5:14 p.m. The equity has experienced a continual decline for years. Hold) without suggesting a price target. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. While it feels cool to buy a thousand shares of OCGN stock vs. a few shares of Amazon (NASDAQ:AMZN), save yourself the heartache. Considering the conditions facing the company, I do not recommend Ocugen stock regardless of risk tolerances. Shares of Ocugen (OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based Bharat Biotech to co-develop a COVID-19 vaccine for the U.S. market. Generally, financial analysts struggle with this sector because these equities rise and fall not on revenue or earnings, but the success of clinical trials. Ocugen has responded to Health Canada regarding deficiencies identified with its regulatory filing for Covaxin. 1125 N. Charles St, Baltimore, MD 21201. Unfortunately, when the market bounced in late March 2020, Ocugen kept heading lower. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Emergency Use Authorization (EUA) for Covaxin, the COVID-19 vaccine developed by Ocugen's partner, Bharat Biotech. Nor should one look forward to OCGN stock to becoming the next GW Pharmaceuticals (NASDAQ:GWPH) or Cara Therapeutics (NASDAQ:CARA). Add in a $31 million market capitalization and potentially significant cash burn, and Ocugen stock self-evidently is not for risk-averse investors. ET on Friday. On June 10, though, Ocugen announced that the U.S. Food and Drug Administration (FDA) had effectively shut the door on an EUA filing. The second is that the balance sheet still needs some help. Do Not Sell My Personal Information (CA Residents Only). Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. The Ocugen deal is a way to salvage some limited value. The combined company has an agreement to sell the rights to NeoCart to privately held Medavate, leaving it reliant on Ocugens pipeline. The average price target among the five analysts covering the stock is $6, suggesting 27.9% downside from current levels. Ocugen executives even sounded cautiously optimistic in the company's fourth-quarter conference call last month. Copyright InvestorPlace - Stock Market News, Stock Advice & Trading Tips. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. For example, after the FDA revised its guidelines for the EUA process for COVID-19 vaccines, Ocugen's CEO stated, "Since we have been in discussions with the FDA since late last year, we do not believe that the FDA's recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for Covaxin as planned." But theres a big difference in having an edge flipping sub-$5 stocks vs. combing over this group as an investor looking for sound fundamentals and a mistakenly low stock price. Sign up below to get this incredible offer! The first is that Ocugen is facing potential delisting from the NASDAQ given that its share price still sits well below $1. Ocugen does have at least 180 days to cure that problem, but the simplest answer is for the company to execute a reverse stock split. However, sometimes the optimism isn't justified. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. market." Thats why we give you a wide range of Options on stocks, indices, commodities and FX. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. The median estimate. Shares of Ocugen ( OCGN -3.10%) fell on Tuesday after an analyst sounded a note of caution to investors. Type a symbol or company name. Maybe OCGN stock will be one of them again. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. The average Ocugen stock price for the last 52 weeks is 2.10. Written by Conditions have only become worse since that time. Ocugen Inc First Quarter 2022 Financial Results and Recent Business Highlights 04/21/2022 Noble Capital Markets' Eighteenth Annual Investor Conference 03/14/2022 34th Annual ROTH Conference 02/25/2022 Ocugen, Inc. Q4 and Full Year 2021 Financial Results and Recent Business Highlights 01/10/2022 H.C. Wainwright Bioconnect Conference 12/22/2021 Indeed, the price broke below the 24 December 2018 low at 4.81 and is currently attempting a return move. That's right -- they think these 10 stocks are even better buys. CEO Shankar Musunuri stated that he was "pleased to say" that Ocugen was in discussions with the FDA about the data it had submitted for the pediatric EUA. The company has no revenue, runs an annual deficit, and does not generate positive free cash flow. More importantly, the 5-star analyst added, COVAXIN also induces comparable levels of neutralizing antibodies to those in human convalescent serum," which, the analyst believes," bodes well for the success of the ongoing Phase 3 trial in India.. Keith Speights has no position in any of the stocks mentioned. Like other life sciences companies involved in Covid-19 vaccine. Type a symbol or company name. The Motley Fool->. If they invent a miracle treatment for a condition, the money will find its way to the stock. Almost all the headlines about Ocugen in the past year have been about the companys COVID-19 vaccine candidate. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. The stock had gained some traction after they announced the Ocugen merger in April. Under the terms of the agreement, Ocugen is entitled to 45% of the profits from the commercialization of Covaxin in the U.S. and Canada. I will concede this: The one great thing about the stock market is there is a style for everyone. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. OCGN does not even appear to have an apparent reason to exist. Most biotech companies have intriguing stories on paper; Ocugen is no different. 2023 InvestorPlace Media, LLC. At the beginning of 2020, Ocugen shares were trading at just 47 cents. The stock had gained some traction after they announced the. Histogenics itself highlights the risks involved in small-cap biotech. The chances of anything more are small but the rewards could be huge. Article printed from InvestorPlace Media, https://investorplace.com/2020/01/ocugen-stock-faint-heart/. If you missed that action, you missed all the gains. Ocugen Inc. is a clinical stage biopharmaceutical company. In that list, you can even include penny-stock trader. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. Investors who have owned stocks in the last year have generally experienced some big gains. Do not expect this to become the biotech who made good like Biogen (NASDAQ:BIIB). It is very important to do your own analysis before making any investment. From a near-term standpoint, there are two key risks. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. The odds of Ocugen stock winding up at zero are material. Without NeoCart, that burn likely comes down. First, the balance sheet is in at least decent shape. Ocugen announced in late Decemberit had signed a letter of intent to co-develop COVID-19 vaccine candidate Covaxin along with Indian pharmaceutical company Bharat Biotech. This requires no immediate effort on your part. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. Ocugen shares jumped to $3.50 on massive volume in December when the Covaxin partnership was announced. Cost basis and return based on previous market day close. With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell Amryt Pharma releases Q-2 how to setup copy trading labrador gold stock that show strong revenue growth as The first split for NKE took place on October 08, Below, we'll pit these two dominant consumer-discretionary giants against each other, with an eye toward long-term . Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. Type a symbol or company name. Part of the proceeds will be used to support its partnership with Bharat. Biotechnology stocks like Ocugen (NASDAQ:OCGN) are among the markets riskiest plays. If youre not convinced by now, maybe you will consider OCGN stock a poor investment when looking at the fundamentals. Source: Chart courtesy of StockCharts.com. Investors should definitely reevaluate Ocugen's prospects in light of the company's bad news announced last week. Lorem ipsum dolor sit amet, consectetur adipiscing elit. But just because a company does not have crippling debt doesnt mean its a buy. Maybe it pans out for Ocugen and I wish the team (and its investors) the best of luck. Matt McCall and the InvestorPlace Research Staff, statistics support having long-term exposure, Click here to see what Matt has up his sleeve now, There Are So Many Stocks to Buy Ocugen Isnt One of Them. Guys, theres no revenue here! Do Not Sell My Personal Information (CA Residents Only). The Ocugen 52-week low stock price is 0.93, which is 1.1% below the current share price. It's easy to become such a huge fan of a stock that you lose objectivity about its prospects. So, what goes wrong? However, an EUA in India doesn't mean that Covaxin is a slam dunk to win EUA in the U.S., as well. At the time, Ocugen was left for dead. The agreement stipulates Ocugen will hold the vaccines U.S. rights, and the remaining details are expected to be finalized over the coming weeks. The stock dropped as low as 26 cents during the height of the pandemic fears in March 2020. The company has a gene therapy platform as well as two preclinical compounds that aim to treat retinal diseases. It has real management. The Motley Fool->. As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. Biotech companies have emerged from similar levels to become huge winners, as evidenced simply by looking at some of the best biotech stocks for 2019. Its top officers have experience at Pfizer (NYSE:PFE) and other well-respected pharmaceutical and biotechnology companies. It means that institutional investors focused on the sector largely have passed on the pipeline. Honestly, OCGN stock is unlikely to survive. On its first trading day as OCGN stock, it lost almost 64% of its value and closed that day at $2.85 per share. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Investors were hopeful that the small drugmaker would be able to win U.S. The S&P 500 has rallied 52.9% from the March low to its highs on August 6. The short answer is: everything. Ocugen. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin. That pathway will likely require the company to conduct further clinical testing of the vaccine in the U.S. Are there any other near-term catalysts for the biotech stock? It's hard to say for sure. You can be a growth investor, futures trader, deep-value investor, a day trader, options player, or a dividend aficionado. Companies will inevitably be optimistic about their prospects for success (at least publicly). We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. Axsome Therapeutics (NASDAQ:AXSM) had an equity value below $75 million in March 2017; its now worth over $3 billion after rising over 1,000% last year. MALVERN, Pa., May 29, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular diseases, today announced that it will present at the 2018 BIO International Convention, taking place June 4-7, 2018, in Boston. quotes delayed at least 15 minutes, all others at least 20 minutes. What should investors do now? You never know when they will suddenly go on a squeeze. COVID-19 vaccines from Pfizer and Moderna are already on the market in the U.S. with efficacy levels of 94% or greater. It has no treatments to offer the market. Considering Bharats reputation for world-class R&D and manufacturing capabilities in vaccines and bio-therapeutics, H.C. Wainwright analyst Swayampakula Ramakanth thinks the company is a suitable partner.. Create your Watchlist to save your favorite quotes on Nasdaq.com. If it goes down, your loss won't be as great as it would be if you held onto all of your shares. To be sure, current cash isnt enough. The FDA told the company in June 2021 that it should instead follow the standard path to full approval of the vaccine in adults. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. Ocugen had to go an unusual route to go public. OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their investment. The Motley Fool has a disclosure policy. These symbols will be available throughout the site during your session. The Motley Fool has no position in any of the stocks mentioned. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. Over the next few weeks, Ocugen is expected to meet with the FDA to discuss how to advance COVAXINs development. Ocugen abandoned its pursuit of a U.S. EUA for Covaxin in immunizing adults last year. For now, though, what happens in India stays in India. ET by MarketWatch Automation Ocugen Inc. stock falls Tuesday, underperforms market Feb. 21, 2023 at 5:14. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. That product drives the current bull case for Ocugen stock. The Motley Fool has no position in any of the stocks mentioned. The FDA typically takes 60 days to accept a regulatory filing then 10 months to make an approval decision. Ocugen hasn't stated yet when a potential late-stage study of Covaxin could start. Thats the thing with these low-priced penny stocks. Ocugen sold $25 million of stock in a private placement before the merger. Ill be sticking to the stocks that are actually working. As of this writing, Vince Martin has no positions in any securities mentioned. Start trading Options with Saxo today. All rights reserved. Bharat Biotech has a history of successful vaccine commercialization in South Asia. Remember, though, that Moderna achieved this while working closely with the U.S. government (including receiving funding from Uncle Sam) and during a period when vaccines weren't widely available. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. A partnership with a respected Asian biotechnology company offers some validation to the pipeline, and a key product is progressing through Phase III trials. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. Create your Watchlist to save your favorite quotes on Nasdaq.com. Shares of Ocugen (OCGN 4.03%) were crashing 19.2% lower as of 11:23 a.m. You could sell some or all of your Ocugen shares and buy long-term call options on the stock. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days later. Malvern-based biopharmaceutical company Ocugen completed its previously announced $100 million private stock sale. Ocugen estimates the drug could have as many as 63,000 potential patients. But there is no question some big-name stocks performed better than others along the way. It peaked at a split-adjusted level of around $778 per share soon after its initial public offering in 2014. It's likely that the company will take longer to file for full FDA approval of the vaccine than Moderna will. As of 1:37 p.m. EST, the biopharmaceutical company's stock price was down more than 15%.. Looking ahead, analysts are skeptical Covaxin will provide the upside Ocugen bulls are expecting. And while Ocugen will need more capital at some point, the company at least has time to push OCU300 forward and get its story out to investors.